HC Wainwright & Co. reiterates Buy rating on SpyGlass Pharma, $37 price target
HC Wainwright & Co. maintained a Buy rating on SpyGlass Pharma with a $37 price target, implying 48.5% upside. The company's BIM-IOL System is in Phase 3 trials, and its acquisition of Advanced Vision Science enhances manufacturing capabilities. The stock closed at $24.92 on Oct 2.
How this was made

The 30-second read
Why it matters
Analyst upgrade could attract buying pressure, but trial outcomes remain uncertain.
Market read
Analyst rating change provides a fresh catalyst for the micro‑cap biotech.
What to watch
Funding needs for Phase 3 trial and regulatory risk
Background
Analyst reiterates Buy rating with $37 price target for SpyGlass Pharma.
Market effects
Potential uplift for glaucoma treatment sector
Limited to US biotech investors
Modest, confined to niche ophthalmology market
Counterpoint
Rating may be premature without trial data release
Key entities
- CompanySpyGlass Pharma
Biotech firm developing intraocular drug delivery system.

